Homeostatic role of transforming growth factor-β in the oral cavity and esophagus of mice and its expression by mast cells in these tissues

American Journal of Pathology

Volumn 174, Issue 6, 2009, Pages 2137-2149

  Vitsky, Allison ^a,b   Waire, James ^a   Pawliuk, Robert ^a,c   Bond, Arden ^a   Matthews, Douglas ^a   LaCasse, Emily ^a   Hawes, Michael L ^a,d   Nelson, Carol ^a   Richards, Susan ^a   Piepenhagen, Peter A ^a   Garman, Richard D ^a   Andrews, Laura ^a   Thurberg, Beth L ^a   Lonning, Scott ^a   Ledbetter, Steve ^a   Ruzek, Melanie C ^a  

^a GENZYME CORPORATION   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

^d Charter Preclinical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITHELIUM HYPERPLASIA; ESOPHAGITIS; ESOPHAGUS; FEMALE; FOOD INTAKE; GINGIVA HYPERPLASIA; GLOSSITIS; HOMEOSTASIS; MAST CELL; MOUSE; MOUTH CAVITY; NONHUMAN; PRIORITY JOURNAL; SALIVA; TOOTH MALFORMATION; WEIGHT REDUCTION;

EID: 67049164997     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080723     Document Type: Article

References (50)

1. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-β. Annu Rev Immunol 1998, 16:137-161 (Pubitemid 28183362)
2. Bonewald LF: Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr 1999, 9:33-44 (Pubitemid 30103917)
3. Piek E, Roberts AR: Suppressor and oncogenic roles for transforming growth factor-β and its signaling pathways in tumorigenesis. Adv Cancer Res 2001, 83:1-54 (Pubitemid 32959260)
4. Yue J, Mulder KM: Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 2001, 91:1-34 (Pubitemid 33055772)
5. Branton MH, Kopp JB: TGF-beta and fibrosis. Microbes Infect 1999, 1:1349-1365
6. Lakos G, Takagawa S, Chen S, Ferriera AM, Han G, Masuda K, Wang X, DiPietro LA, Varga J: Targeted disruption of TGF-β/SMAD3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004, 165:203-217 (Pubitemid 38821828)
7. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699
8. Kulkarni AB, Huh C, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993, 90:770-774 (Pubitemid 23028947)
9. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 1995, 155:3205-3212
10. Levéen P, Larsson J, Ehinger M, Cillo CM, Sundler M, Sjöstrand LJ, Holmdahl R, Karlsson S: Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 2002, 100:560-568 (Pubitemid 34761120)
11. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D, Li AG, Tang CF, Siddiqui Y, Nord J, Andersen P, Corless CL, Wang XJ: Loss of transforming growth factor-beta type II receptor promotes metastatic head and neck squamous cell carcinoma. Genes Dev 2006, 20:1331-1342 (Pubitemid 43727593)
12. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851 (Pubitemid 38174665)
13. Hahm KB, Lee KM, Kim YB, Hong WS, Lee WH, Han SU, Kim MW, Ahn BO, Oh TY, Lee MH, Green J, Kim SJ: Conditional loss of TGF-beta signaling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther 2002, 16(Suppl 2):115-127 (Pubitemid 41771470)
14. Beck PL, Rosenberg IM, Xavier RJ, Koh T, Wong JF, Podolsky DK: Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am J Pathol 2003, 162:597-608 (Pubitemid 36267866)
15. Ruzek MC, Hawes MH, Pratt B, McPherson J, Ledbetter S, Richards SM, Garman RD: Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 2003, 25:235-257 (Pubitemid 36597420)
16. Strockbine NA, Marques LR, Holmes RK, O'Brien AD: Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 1985, 50:695-700 (Pubitemid 16216861)
17. Danielpour D, Dart LL, Flanders KC, Roberts AB, Sporn MB: Immunodetection and quantitation of two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J Cell Physiol 1989, 138:79-86 (Pubitemid 19038674)
18. Latimer KS, Prasse KW: Leukocytes. Duncan and Prasse's Veterinary Laboratory Medicine Clinical Pathology, ed 4. Edited by Latimer KS, Mahaffey EA, Prasse KW. Ames, Iowa State Press, 2003, pp 46-79
19. Leininger JR, Jokinen, Dangler CA, Whiteley LO: Oral cavity, esophagus, and stomach. Pathology of the Mouse. Edited by Maronpot RR, Boorman GA, Gaul BW. Vienna, Cache River Press, 1999, pp 36-37
20. Long PH, Leininger JR: Teeth. Pathology of the Mouse. Edited by Maronpot RR, Boorman GA, Gaul BW. Vienna, Cache River Press, 1999, p 16
21. Prime SS, Pring M, Davies M, Paterson IC: TGF-beta signal transduction in oro-facial health and non-malignant disease (part 1). Crit Rev Oral Biol Med 2004, 15:324-336 (Pubitemid 44567521)
22. D'Souza RN, Cavender A, Dickinson D, Roberts A, Letterio J: TGFbeta1 is essential for the homeostasis of the dentin-pulp complex. Eur J Oral Sci 1998, 106(Suppl 1):185-191 (Pubitemid 128737224)
23. Davis BJ, Dixon D, Herbert RA: Ovary, oviduct, uterus, cervix, and vagina. Pathology of the Mouse. Edited by Maronpot RR, Boorman GA, Gaul BW. Vienna, Cache River Press, 1999, pp 440-444
24. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS: Hepatic expression of mature transforming growth factor b1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995, 92:2572-2576
25. McLennan IS, Koishi K: Fetal and maternal transforming growth factor-beta 1 may combine to maintain pregnancy in mice. Biol Reprod 2004, 70:1614-1618 (Pubitemid 38715615)
26. Wozniak KL, Arribas A, Leigh JE, Fidel PL Jr: Inhibitory effects of whole and parotid saliva on immunomodulators. Oral Microbiol Immunol 2002, 17:100-107 (Pubitemid 34414260)
27. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350-1358 (Pubitemid 30408720)
28. Belizario JE, Dinarello CA: Interleukin 1, interleukin 6, tumor necrosis factor, and transforming growth factor β increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle. Cancer Res 1991, 51:2379-2385
29. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J: Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990, 62:175-185 (Pubitemid 20216297)
30. Borkowski TA, Letterio JJ, Farr AG, Udey MC: A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med 1996, 184:2417-2422 (Pubitemid 27023742)
31. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234
32. Tato CM, O'Shea JJ: Immunology: what does it mean to be just 17? Nature 2006, 441:166-168
33. Gorham JD, Lin JT, Sung JL, Rudner LA, French MA: Genetic regulation of autoimmune disease: BALB/c background TGF beta 1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J Immunol 2001, 166:6413-6422 (Pubitemid 32440776)
34. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T: Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 1995, 92:12215-12219 (Pubitemid 26014041)
35. Izcue A, Coombes JL, Powrie F: Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006, 212:256-271 (Pubitemid 44116713)
36. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, Gautam S, Moses HL, Grady WM: Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004, 64:4687-4692 (Pubitemid 38924506)
37. Sakuraba H, Ishiguro Y, Yamagata K, Munakata A, Nakane A: Blockade of TGF-beta accelerates mucosal destruction through epithelial cell apoptosis. Biochem Biophys Res Commun 2007, 359:406-412 (Pubitemid 46898965)
38. Kvidera A, Mackenzie IC: Rates of clearance of epithelial surfaces of mouse oral mucosa and skin. Epithelial Cell Biol 1994, 3:175-180
39. Kellett M, Potten CS, Rew DA: A comparison of in vivo cell proliferation measurements in the intestine of mouse and man. Epithelial Cell Biol 1992, 1:147-155
40. Seymour RA, Thomason JM, Ellis JS: The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996, 23:165-175 (Pubitemid 126731916)
41. Das SJ, Newman HN, Olsen I: Keratinocyte growth factor receptor is up-regulated in cyclosporine A-induced gingival hyperplasia. J Dent Res 2002, 81:683-687
42. Grönblad EA: Concentration of immunoglobulins in human whole saliva: effect of physiological stimulation. Acta Odontol Scand 1982, 40:87-95 (Pubitemid 12030241)
43. Sayed BA, Christy A, Quirion MR, Brown MA: The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 2008, 26:705-739 (Pubitemid 351600390)
44. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ: Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007, 8:1095-1104 (Pubitemid 47423757)
45. Byrne SN, Limón-Flores AY, Ullrich SE: Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. J Immunol 2008, 180:4648-4655
46. Hochegger K, Siebenhaar F, Vielhauer V, Heininger D, Mayadas TN, Mayer G, Maurer M, Rosenkranz AR: Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 2005, 35:3074-3082 (Pubitemid 41568074)
47. Lu, L-F, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, Strom TB, Zheng XX, Noelle RJ: Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442:997-1002 (Pubitemid 44330250)
48. Ozbilgin MK, Inan S: The roles of transforming growth factor type beta 3 (TGF-beta3) and mast cells in the pathogenesis of scleroderma. Clin Rheumatol 2003, 22:189-195 (Pubitemid 37258511)
49. Lançoni G, Ravinal RC, Costa RS, Roselino AM: Mast cells and transforming growth factor-beta expression: a possible relationship in the development of porphyria cutanea tarda skin lesions. Int J Dermatol 2008, 47:575-581 (Pubitemid 351676497)
50. Chen W, Jin W, Tian H, Sicurello P, Frank M, Orenstein JM, Wahl SM: Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med 2001, 194:439-453 (Pubitemid 32835040)